USFDA accepts for review Dr Reddy's biologics license application for Orencia biosimilar DRL_AB Swati Bharadwaj Hyderabad: Dr Reddy’s Laboratories Ltd.

US FDA accepts for review Dr Reddy’s BLA for proposed interchangeable biosimilar, abatacept: Our Bureau, Bengaluru Monday, February 23, 2026, 12:20 Hrs [IST] Dr Reddy’s Labora ...

With the ninth-generation Hilux already unveiled globally in November 2025, Fortuner’s arrival in new-gen form was inevitable ...

Nomura India said DRL's acquisitions over the past five years may contribute around one-quarter of the company’s revenues in ...

TRENTON — A couple of Downriver League girls basketball teams continued their respective late-season pushes when Wyandotte Roosevelt and Trenton held their second head-to-head meeting of the season on ...

Dr. Reddy’s Laboratories (RDY) stock is in focus as the FDA agrees to review its biosimilar targeting Bristol Myers' (BMY) ...

A couple of Downriver League girls basketball teams continued their respective late-season pushes when Wyandotte Roosevelt and Trenton held their second head-to-head meeting of the season on Wednesday ...

Dr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimilars, anticipating significant growth within five years.

Aftermarket lighting specialist Morimoto has introduced new LED headlights for the C6 Corvette, serving up an overview and ...

The US Food and Drug Administration (USFDA) has greenlit Dr Reddy's Biologics License Application for a proposed biosimilar to Orencia (abatacept).

Dr. Reddy’s announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.

Joao Kleber Amaral, the virtual artist behind 'joaokleberdesign' on social media, has recently worked for motor.es to unravel the secrets of these new EVs ...